title: Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection.
abstract: BACKGROUND
  Few studies have investigated the impact of chronic hepatitis B and C infection on antiretroviral therapy (ART) outcomes in sub-Saharan Africa. Hepatotoxicity may be a particular concern in co-infected patients taking nevirapine-stavudine-lamivudine.
  
  
  METHODS
  We conducted a prospective cohort study of 300 Malawian adults starting ART and describe one-year ART outcomes according to viral hepatitis status.
  
  
  RESULTS
  At baseline, patients had advanced HIV disease (29.3% were in WHO stage 4; mean CD4 = 157 cells/microL; mean log(10)HIV-1 RNA = 5.24 copies/ml). Co-infection with hepatitis B, C and B + C were present in 6.7%, 5.7% and 1.7% respectively. At 50 weeks, all-cause mortality was 43 (14.3%). Sixteen (5.3%) had transferred to another unit. Eight (2.7%) were lost to follow up. Sixteen (5.3%) had stopped ART. 217 (72.3%) were alive on ART, of whom 82.5% had an HIV-1 RNA <400 copies/ml at week 50. During the first 50 weeks of ART, severe hepatotoxicity (liver enzyme values >5 times upper level of normal) occurred in 9%, but did not result in any ART discontinuations. Clinical hepatitis or jaundice was not observed. There were no significant differences in occurrence of hepatotoxicity, other side effects, mortality, severe morbidity, immune reconstitution or virological failure between hepatitis B and/or C co-infected patients and those who were not. Viral hepatitis co-infection was not associated with severe hepatotoxicity, mortality, severe morbidity or virological failure in multivariate analyses.
  
  
  CONCLUSIONS
  Our data suggest that screening for viral hepatitis B and C and liver enzyme monitoring may not require high priority in ART programmes in sub-Saharan Africa.
authors.affiliation: Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.
authors.forename: E
authors.initials: E
authors.lastname: Moore
authors.forename: M B J
authors.initials: MB
authors.lastname: Beadsworth
authors.forename: M
authors.initials: M
authors.lastname: Chaponda
authors.forename: B
authors.initials: B
authors.lastname: Mhango
authors.forename: B
authors.initials: B
authors.lastname: Faragher
authors.forename: J
authors.initials: J
authors.lastname: Njala
authors.forename: H W C
authors.initials: HW
authors.lastname: Hofland
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: I J
authors.initials: IJ
authors.lastname: Hart
authors.forename: N J
authors.initials: NJ
authors.lastname: Beeching
authors.forename: E E
authors.initials: EE
authors.lastname: Zijlstra
authors.forename: J J
authors.initials: JJ
authors.lastname: van Oosterhout
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1; D019694:Hepatitis B, Chronic / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008295:Malawi; D008297:Male; D011247:Pregnancy; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents